Journey Medical (NASDAQ:DERM – Get Free Report) and Dyne Therapeutics (NASDAQ:DYN – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, dividends, earnings, valuation and risk.
Institutional & Insider Ownership
7.3% of Journey Medical shares are owned by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are owned by institutional investors. 15.0% of Journey Medical shares are owned by insiders. Comparatively, 14.1% of Dyne Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Risk & Volatility
Journey Medical has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500. Comparatively, Dyne Therapeutics has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Journey Medical | $56.13 million | 3.58 | -$14.67 million | ($0.35) | -21.84 |
| Dyne Therapeutics | N/A | N/A | -$317.42 million | ($3.66) | -5.70 |
Journey Medical has higher revenue and earnings than Dyne Therapeutics. Journey Medical is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Journey Medical and Dyne Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Journey Medical | 1 | 1 | 3 | 0 | 2.40 |
| Dyne Therapeutics | 1 | 3 | 10 | 4 | 2.94 |
Journey Medical currently has a consensus price target of $12.17, indicating a potential upside of 59.15%. Dyne Therapeutics has a consensus price target of $34.93, indicating a potential upside of 67.58%. Given Dyne Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Dyne Therapeutics is more favorable than Journey Medical.
Profitability
This table compares Journey Medical and Dyne Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Journey Medical | -14.58% | -39.94% | -10.45% |
| Dyne Therapeutics | N/A | -64.12% | -56.75% |
Summary
Dyne Therapeutics beats Journey Medical on 8 of the 14 factors compared between the two stocks.
About Journey Medical
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.
About Dyne Therapeutics
Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Receive News & Ratings for Journey Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Journey Medical and related companies with MarketBeat.com's FREE daily email newsletter.
